Cardiff Oncology Inc Cash Flow Conversion Efficiency
Cardiff Oncology Inc cash flow conversion efficiency. Based on the latest financial reports, Cardiff Oncology Inc (CRDF) has a cash flow conversion efficiency ratio of -0.131x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.97 Million) by net assets ($45.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cardiff Oncology Inc (2009–2025)
Cash flow conversion efficiency of Cardiff Oncology Inc from 2009 to 2025. This chart illustrates how Cardiff Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cardiff Oncology Inc stock quote for real-time trading data and today's change.
Cardiff Oncology Inc Cash Flow Conversion Ratio Explained
Cardiff Oncology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cardiff Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardiff Oncology Inc ranked by their cash flow conversion efficiency. Also see market cap of Cardiff Oncology Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AmFIRST Real Estate Investment Trust
KLSE:5120
|
0.041x |
|
Genohco Inc.
KQ:361390
|
-0.137x |
|
Vitura S.A.
PA:VTR
|
-0.013x |
|
Inta Bina Group Bhd
KLSE:0192
|
0.047x |
|
Kamux Suomi Oy
HE:KAMUX
|
0.181x |
|
Multifiling Mitra Indonesia
JK:MFMI
|
0.602x |
|
Mospec Semiconductor Corp
TW:2434
|
-0.006x |
|
Fiducial Office Solutions
PA:SACI
|
-0.086x |
Annual Cash Flow Conversion Efficiency for Cardiff Oncology Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Cardiff Oncology Inc from 2009 to 2025. Review CRDF cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $45.39 Million | $-37.92 Million | -0.836x | -83.87% |
| 2024-12-31 | $82.95 Million | $-37.69 Million | -0.454x | -2.60% |
| 2023-12-31 | $69.74 Million | $-30.89 Million | -0.443x | -39.26% |
| 2022-12-31 | $106.34 Million | $-33.82 Million | -0.318x | -93.82% |
| 2021-12-31 | $140.42 Million | $-23.04 Million | -0.164x | -28.89% |
| 2020-12-31 | $128.16 Million | $-16.31 Million | -0.127x | +92.98% |
| 2019-12-31 | $7.31 Million | $-13.27 Million | -1.815x | -38.63% |
| 2018-12-31 | $10.08 Million | $-13.20 Million | -1.309x | +63.42% |
| 2017-12-31 | $6.51 Million | $-23.28 Million | -3.578x | -127.89% |
| 2016-12-31 | $19.77 Million | $-31.04 Million | -1.570x | -245.73% |
| 2015-12-31 | $48.70 Million | $-22.12 Million | -0.454x | +70.21% |
| 2014-12-31 | $8.35 Million | $-12.73 Million | -1.524x | -324.83% |
| 2013-12-31 | $20.39 Million | $-7.32 Million | -0.359x | +84.23% |
| 2012-12-31 | $2.17 Million | $-4.93 Million | -2.275x | -598.70% |
| 2011-12-31 | $-4.23 Million | $-1.93 Million | 0.456x | +9.10% |
| 2010-12-31 | $-5.00 Million | $-2.09 Million | 0.418x | +28.84% |
| 2009-12-31 | $-3.79 Million | $-1.23 Million | 0.325x | -- |
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more